文献速递淋巴瘤

miR-150-5p/E2F3/survivin轴在浆母细胞淋巴瘤发病机制中的作用及其治疗潜力

The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential.
PubMed 文献 · Blood Adv · 2025-01-01

本研究通过RNA测序和微阵列分析浆母细胞淋巴瘤(PBL)的转录组,发现细胞周期相关基因(包括MYC和E2F靶基因)及G2/M检查点基因富集,并鉴定出依赖MYC转位存在的两种microRNA表达特征。在PBL-1细胞中上调miR-150-5p可诱导G1期细胞周期阻滞、通过转录抑制E2F3抑制增殖、并通过下调BIRC5促进凋亡;联合抑制E2F3和survivin在PBL细胞及绒毛尿囊膜来源的异种移植模型中减弱淋巴瘤发生并抑制肿瘤生长。

要点

  • PBL转录组富集细胞周期相关基因(MYC、E2F靶基因)及G2/M检查点基因。
  • PBL中miR-150-5p下调,而E2F3和BIRC5(survivin)上调。
  • 联合抑制E2F3和survivin在PBL细胞及绒毛尿囊膜异种移植模型中减弱淋巴瘤发生并抑制肿瘤生长。

核心结论

  • miR-150-5p/E2F3/survivin轴在促进PBL淋巴瘤发生中起关键作用,并揭示了该淋巴瘤的新治疗靶点。

研究设计与样本

  • 研究对PBL进行转录组分析,采用RNA测序和微阵列分析,并在PBL-1细胞及绒毛尿囊膜来源的PBL异种移植模型中进行功能实验。

主要发现

  • RNA测序发现PBL中细胞周期相关基因(包括MYC和E2F靶基因)及G2/M检查点相关基因富集。
  • 微阵列分析发现两种microRNA表达特征,取决于MYC转位是否存在。
  • PBL中miR-150-5p下调,而细胞周期激活因子E2F3和抗凋亡调节因子BIRC5(survivin)上调。
  • 在PBL-1细胞中增加miR-150-5p诱导G1期细胞周期阻滞、通过转录抑制E2F3抑制增殖、并通过下调BIRC5促进凋亡。
  • 在E2F3敲低细胞中miR-150-5p的肿瘤抑制活性减弱;联合抑制E2F3和survivin在PBL细胞中减弱淋巴瘤发生,并在绒毛尿囊膜来源的PBL异种移植模型中抑制肿瘤生长。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasmablastic lymphoma (PBL) is an uncommon and aggressive B-cell lymphoma with a poor prognosis. Some studies have described genetic alterations in PBL, but its transcriptome has been scarcely studied, and molecular mechanisms driving lymphomagenesis remain poorly understood. Our goal was to delineate transcriptomic profiles to identify potential biomarkers for novel targeted therapy in PBL. RNA sequencing uncovered an enrichment of cell cycle-related genes, including MYC and E2F targets, and genes involved in G2/M checkpoint in PBL. Microarray analyses discovered 2 microRNA expression signatures depending on the presence of MYC translocation. Interestingly, miR-150-5p was downregulated, whereas E2F3 and BIRC5 (survivin), a cell cycle activator and an antiapoptotic regulator, respectively, were upregulated. Increasing miR-150-5p in PBL-1 cells induced G1 cell cycle arrest, suppressed proliferation by transcriptionally repressing E2F3, and promoted apoptosis by the downregulation of BIRC5. Interestingly, the miR-150-5p tumor suppressor activity was diminished in E2F3-knockdown cells. The combined inhibition of E2F3 and survivin attenuated lymphomagenesis in PBL cells and suppressed tumor growth in a chorioallantoic membrane-derived xenograft model of PBL. Overall, our study highlights the pivotal role of the miR-150-5p/E2F3/survivin axis in boosting PBL lymphomagenesis and unveils new therapeutic targets for this lymphoma.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Verdú-Bou M, Baptista MJ, Ribeiro ML, et al. The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential. Blood Adv. 2025. PMID: 40203244. doi:10.1182/bloodadvances.2025016180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。